Abstract: Critical limb ischemia (CLI) is associated with significant morbidity and mortality. In this study, we developed and characterized an intra-arterial cell suspension containing human mesenchymal stem cells (hMSCs) for the treatment of CLI. Equally, the stability of cells was studied in order to evaluate the optimal conditions of storage that guarantee their viability from cell processing to the administration phase. The effects of various factors, including excipients, storage temperature and time were evaluated to analyze the survival of hMSCs in the finished medicinal product. The viability of hMSCs in different packaging media was studied for 60 h at 4 ºC. The best medium maintaining hMSCs viability was then selected to test storage conditions (4, 8, 25 and 37 ºC; 60 h). The results showed that at 4 ºC the viability was maintained above 80% for 48 h, at 8 ºC decreased slightly, whereas at room temperature and 37 ºC decreased drastically. Its biocompatibility was assessed by cell morphology and cell viability assays. During stability study, the stored cells did not show any change in their phenotypic or genotypic characteristics and physicochemical properties remained unchanged, the ability to differentiate into adipocytes and osteocytes and sterility requirements were also unaltered. Finally, our paper proposes a packing media composed of albumin 20%, glucose 5% and stored at 4 ºC as suitable for maintaining cells viability (> 80%) and without altering their characteristics for more than 48 h.
INTRODUCTION
The recent advances of biomedical research and biotechnologies have opened new promising therapeutic strategies, and human mesenchymal stem cells (hMSCs) are attracting increasing interest for possible application in cell therapies for the treatment of several human diseases [1, 2] . hMSCs offer considerable therapeutic potential through the development of different cell therapy medical products (CTMP) for clinical use [3] , due to their regenerative and immunoregulatory capacities [4, 5] , which have made them one of the most promising candidates for cell therapy success including regenerative and immune therapies where present conventional treatments are inadequate.
Critical limb ischemia (CLI) is one of the diseases most studied in the field of cell therapy, in particular in diabetic patients, CLI of the leg develops earlier and more intensely, avoiding revascularization [6, 7] CLI is a syndrome manifested by ischemic rest pain, non-healing ulcers, tissue loss and gangrene. The incidence of CLI is estimated to be approximately 500 to 1000 patients per million and year [8] . Patients with CLI are at high risk of amputation, increased in diabetic patients, which leads to a low quality of life, and severe morbidity and mortality, resulting in a significant social and economic impact [9] .
Currently the latest advances in this pathology have led to the development of new drugs with stem cells as an alternative to surgical and pharmacological treatment.
hMSCs transplantation is one of the most studied therapeutic alternatives in preclinical and clinical stages, to be due to paracrine, immunomodulatory, and differentiation effects [8, 10, 11] .
hMSCs encompass a broad range of anchorage dependent fibroblast-like cells which can be obtained from bone marrow aspirates, skeletal muscle connective tissue, human trabecular bones, adipose tissue, periosteum, fetal blood and liver, and umbilical cord blood [12] . These cells are characterized by being able to adhere to plastic. They can proliferate in vitro and exhibit multilineage differentiation capacity being capable to give rise to diverse cells like osteoblasts, chondrocytes, adipocytes, myocytes, tenocytes and vascular cells and to express several common cell surface antigens [13] .
Adipose tissue-derived stem cells have emerged as a new and promising type of stem cells because adipose tissue is an abundant source of stem cells, it lacks donor limitation and it is possible to obtain by a minimally invasive method [14] .
Conducting cellular therapeutics is a complex undertaking, and both safety and efficacy measures shall be considered in the establishment of the manufacturing process of a finished medicinal product for cell therapy [15] among all steps involved, research phase, translational phase for scaling-up the protocol for the clinical requirements, establishment of standard operation procedures (SOP), validation runs, regulatory registration, storage and transportation [16] . The use of hMSCs for clinical application requires a high number of cells, which entails the in vitro expansion in a certified laboratory under good manufacturing practice (GMP) conditions [17] . After culturing and having obtained the necessary number of cells, hMSCs must be loaded in a suitable dosage form for their administration. hMSCs can be formulated into liquid and semisolid dosage forms. Current methods of cell delivery involve the use of injections and microencapsulation. The use of several biomaterials for microencapsulation results in an impenetrable membrane to cells, and requires strong mechanical disturbances such as pressurized nozzles, emulsification, or stirring during droplet generation leading to cell degradation [18] . A cell suspension can be parentally administered directly in the damaged organ/tissue whilst offering medical devices use possibility. Attempts of CLI treatment with intra-arterial hMSCs have been associated with significant therapeutics benefits [10] .
On the other hand, the administration of the cells to the patient is not unmediated. After obtaining the cells, the formulation of the finished medicinal product is carried out, all quality checks must be performed before approving its release, hence cells must be stored and transported in the best conditions to maintain stability [19] . The finished medicinal product of a CTMP includes an active ingredient (hMSCs) and the selected excipients (packaging medium), which are different from the expansion media. The cell stability of the finished medicinal product is determinant for its therapeutic applications in clinical use since baseline characteristics of cells should be maintained [15] .
The stability information should include biological (sterility including mycoplasma, endotoxin and adventitious viral agents, identity, purity and potency) and physicochemical tests including those related to the design of the dosage form such as cell sedimentation rate and resuspension [20] . Alternatively, these products are likely to have a short shelf-life, which often means that these products are administered to patients before current sterility test results are available [17] . Due to cells are highly fragile and sensitive to their surrounding environment, and in order to maintain their quality, their environment needs to be strictly controlled during the time gap between cell harvesting and administration. Therefore, for the formulation of a cell suspension, important key factors must be taken into account, such as selection of the excipients of the packing medium, which must be protein-free, to avoid inflammatory responses affecting the efficacy and safety [21] . Temperature and time conditions of storage as well as transport should be also studied.
Even though characterization of hMSCs has been extensively studied for their in vitro expansion, however there are not data about the cell characterization in the finished medicinal product. The present work studies the stability of MSCs from human adipose tissue elaborated in a cell suspension for intra-arterial application.
The choice of the packing medium and storage conditions for a hMSCs suspension have been studied through stability studies, with the purpose of formulating a finished medicinal product that assured the maintenance of the characteristics more similar as possible to those of native hMSCs. hMSCs have been characterized before and after formulation, studying cell viability, immunophenotypic and genotypic characterization, differentiation, microbiology and physicochemical properties.
MATERIALS AND METHODS

GMP environment
This study was performed in the context of a clinical trial, in phase I/II under GMP conditions. All procedures were performed in a certified clean room at the Center for Molecular Biology and Regenerative Medicine (CABIMER), it was the first laboratory accredited by the Spanish Agency for Medicines and Medical Devices for production of stem cells as medicines in Andalucía (Spain).
All starting materials and reagents required for this study were according to GMP guidelines. All equipment was validated.
Human mesenchymal stem cell isolation and culture from adipose tissue
The donor source of the hMSCs was appropriately screened and tested for human pathogens. Procedures were performed at the San Lazaro Hospital (Spain). The therapeutic protocol was approved by the hospital ethics committee in accordance with Spanish law. All patients signed a detailed informed consent form before intervention and gave their consent for publication of the study results. This study was conducted in accordance with the ethical standards of the Helsinki Declaration (1975). In particular, the presence of Human Immunodeficiency Virus (HIV), hepatitis B and hepatitis C virus were analyzed. On the other hand, all starting materials and reagents required for the expansion were analyzed to certify that they were sterile and endotoxin-free.
Autologous hMSCs were isolated from adipose tissue by enzymatic digestion with collagenase (2 mg collagenase/1 g adipose tissue) (Roche Farma, Reinach, BL, Switzerland). Briefly, the sample was centrifuged at 400 g for 10 min, filtered and washed with Phosphate Buffered Saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA).
The isolated cells were suspended and plated at medium density (passage 0) of 1220 Louis, MO, USA). After 24 h non adherent cells were removed by replacing the expansion medium. Cells were harvested upon reaching 80% confluence, and subcultured using 0.25% trypsin (Gibco, Invitrogen, Grand Island, NY, USA) on expansion medium, and plated at medium density of 35005500 cells/cm 2 . Cells were cultured in a 95% relative humidity, incubator at 37 °C in 5% CO 2 . The medium was completely replaced every 2 or 3 days a week.
Cell viability and counting assay
This study was conducted before and after the preparation of the finished medicinal product, in the supernatant and in each packaging media.
Cell viability was determined by trypan blue dye exclusion staining [22] Spain) were selected to analyze the hMSCs viability during the storage period of the finished cell medicinal product. Four packaging media were prepared, the excipients for 50 mL of each such media is reported in Table 1 .
hMSCs were packed in 10mL Luer-lock syringes (Becton Dickinson and Company, Franklin Lakes, NJ, USA). 11 syringes for each medium were prepared and stored at 4 ºC in a normal atmosphere. Every 6 h for 60 h, cell viability was tested.
Influence of the temperature of storage
hMSCs were packed in 24 10mL-Luer-lock syringes (Becton Dickinson and Company, Franklin Lakes, NJ, USA) at a concentration of 1  10 6 cells/mL with 1 mL of the most stable packing medium after the study described above. Samples were stored at different temperature: 4 ºC, 8 ºC, 25 ºC and 37 ºC in normal atmosphere (6 syringes each temperature). Cell viability was tested every 12 h for 60 h.
hMSCs immunophenotypic characterization
At passage 4 and after stability study of the finished medicinal product, 
In vitro osteogenic and adipogenic differentiation
The differentiation of hMSCs into osteoblasts and adipocytes was analyzed on passage 4 and after stability study of the finished medicinal product. Tokyo, Japan) and a CCD camera (Olympus DP70).
hMSCs karyotyping analysis
The hMSCs were analyzed before and after the stability study. Karyotype analysis was performed by G band techniques [24] . In order to obtain chromosomal preparations the hMSCs were treated with 0.8 g/mL colchicines (KaryoMAX  -Colcemid; Gibco, Invitrogen, Grand Island, NY, USA) and incubated at 37 ºC for 1.15 h. Briefly the cells were washed with 1 mL trypsin (Gibco, Invitrogen, Grand Island, NY, USA) twice.
Then, 2 mL trypsin was added at 37 ºC for 2 min and centrifuged at 400 g for 10 min with 1 mL FBS. The pellet was suspended in 5 mL 75 mM KCl (Merck, Darmstadt, Germany) at 37 ºC for 20 min and centrifuged at 400 g for 10 min. The cells were fixed with 5 mL methyl alcohol-acetic acid mixture (3:1 v/v) (Merck, Darmstadt, Germany) and centrifuged at 400 g for 10 min., this process was repeated twice more. For each karyotype 30 metaphases were analyzed. The final result was described to account the recommendations from the International System for Human Cytogenetic Nomenclature
[25]. Chromosomal aberrations were considered when at least two metaphases showed the same alteration (additions, deletions, inversions and translocations).
Microbiological studies
Microbiological analysis was based on the study of the sterility of the cells before being packaged and sterility of the finished medicinal product after stability study. The test was carried out as described in the European Pharmacopoeia [26] , Data from the flow curve (when resulted to be non-newtonian) were fitted to different mathematical models, equations (2) -(6) using the Prism  , V. 3.00 software (GraphPad Software Inc., San Diego, CA, USA):
Where is the τ is the shear stress (Pa),  is the viscosity (Pa·s),  is the shear rate 
Statistical analysis
Tests for significant differences between means were performed by Student's t-test or one-way ANOVA using the Prism  , V. 3.00 software (GraphPad Software Inc., San Diego, CA, USA). Differences where p < 0.05 were considered statistically significant.
Experiments were repeated on three different samples and the results were expressed as mean ± standard deviation (SD). Although generally NaCl 0.9% is the vehicle of choice for any parenteral suspension, our study demonstrated that it was the medium in which viability decreased, and thus the least suitable. These results indicated greater cell viability in media with albumin and nutrients. Whilst, media 3 and 4 were solutions lacking of essential nutrients causing a rapid and significant decreased of cell viability.
RESULTS AND DISCUSSION
In general there was a progressive loss of viability but the results indicated that hMSCs had better survival rate when they were packed in medium 1 as compared to the packaging media 2, 3 and 4.
Influence of the temperature of storage
Taking into account results above described, the effect of storage temperature was However at 4 ºC the viability of hMSCs remained above 80% (83.4  1.1%) up to 48 h, being the temperature most suitable for maintaining the viability of the cells for longer.
hMSCs immunophenotypic characterization
hMSCs packed in medium 1 and stored at 4 °C after 48 h were analyzed by a flow cytometer. The results were compared with previous storage test results (cell on passage 4). Analysis revealed that both populations (before and after packing) were positive (>95%) for mesenchymal markers (CD13, CD29, CD90 and CD105) and were negative (<10%) for endothelial and hematopoietic lineage markers (CD34, CD45, CD31 and HLA-II) as is shown in Fig. 3 . Fluorescence cytometry between hMSCs in both cultures and finished medicinal product showed no differences when the hMScs were stored at 4 ºC for 48 h in medium 1.
In vitro osteogenic and adipogenic differentiation
hMSCs were seeded and cultured in osteogenic and adipogenic media again to confirm if hMSCs packed and stored in the medium 1 at 4 ºC after 48 h could differentiate into osteoblasts and adipocytes. The results were compared with differentiation conducted on passage 4, before the stability test performed (Fig. 4) . The differentiation was confirmed following the standard protocols and no difference was observed in the differentiated cells indicating that storage at 4 ºC for 48 h in the medium 1 did not affect the differentiation capability of hMSCs.
hMSCs karyotyping analysis
Cells were tested for genomic stability using a conventional analysis by G band techniques to check whether the hMSCs maintained their normal karyotype during cultivation to passage 4 and during their packing and storage before their administration phase. The results showed that on passage 4, the hMSCs were normal diploid karyotype (46, XX). After packaging and storage phases in medium 1 at 4 ºC for 48 h, a sample contained in a sterile syringe Luer-lock, was taken to carry out another karyotype test.
The results of these test showed no karyotype changes in the finished medicinal product, obtaining a normal diploid karyotype (46, XX) (Fig. 5) .
Microbiological studies
Sterility testing was performed on the hMSCs during culture (passage 4) and packing after stability study to ensure no contamination. When the incubation period had finished all tested samples were observed and no turbidity was exhibited, and so completely free of contaminating microorganisms. These results showed that not only the expansion procedure maintained asepsis, but also package and storage in medium 1, for 48 h at 4 °C, preserved the sterility of the finished medicinal product until administration phase. All negative control tubes were negative after the required incubation period. For this reason the rheological characteristics of unstirred cell suspension were also studied. The sample exhibited Newtonian behavior and has lower viscosity value (1.11 ± 0.06 mPas), which indicated that there was migration of aggregates/flocculates. To distinguish both alternatives suspensions were studied after being shaken. Most aggregates were separated as consequence of shear forces, which will be sufficient to break-up the weak reversible flocculation. Viscosity value of the finished cell suspension in this case was 1.575 ± 0.043 mPas. This value is similar to viscosity of blood plasma of 1.2 mPa s at 37 ºC [36] .
The flow and viscosity curves of the suspensions (shear stress versus shear rate in red, and viscosity versus shear rate in blue) are shown in Fig. 6 . When the shear rate increases, the viscosity values decrease, and this tendency is exhibited in all samples.
This rheological behaviour could be described as typical for a non-Newtonian, parameters and covers the entire shear rate range [37] . In general, the four parameter models are difficult to apply because there is seldom enough data to allow good model fitting. However, they represent the best results in predicting the behaviour of nonNewtonian fluids. These results may have important implications for the administration because the success of the injection is dependent upon limiting shear forces of the needle wall causing cell lysis mainly produced by turbulent flow.
Morphological analysis
To determine whether the hMSCs cultures maintained their morphologic characteristics, they were tested in each passage and before packing. The adherent cultured hMSCs exhibited a homogeneous population with a fibroblast-like morphology when observed under a light microscope before to be packed. Following the stability test, no morphological differences were observed when the cells were plated again.
On the other hand, the packed hMSCs in medium 1 at different temperatures (4, 8, 25 and 37 ºC for 48 h, were observed each 12 h to determine if cell aggregation may have occurred. Imagines showed no cell aggregation at 4 and 8 ºC at any time (Fig. 7) .
However, at room temperature and 37 ºC, after 24 hours cell aggregate signs could be seen. Therefore it can be concluded that the packaged finished medicinal product in medium 1, at 4 ºC for 48 h did not exhibited hMSCs aggregation in suspension and was safe to be administrated. The region below 4 mm marks the metal base and the strong decay of backscattering above 38 mm the beginning of the free surface of the sample.
For cell suspension both creaming and flocculation mechanisms, were involved. It can be observed that the initial dispersion presented a backscattering value about 5% and there were no changes in backscattering for the first 2 h. Between 2 and 6 h, a progressive backscattering increase was observed. This phenomenon could be attributed to the sample flocculation, possibly due to the formation of aggregates, as it was previously observed in microscopy study. These result confirmed the natural preference of hMSCs to form [39] . In our samples, flocculation started at different times.
The peak that appeared at the top of the tube was indicative of creaming, presumably caused for migration of cellular components as lipid membranes from dead cells.
Finally, after about 7 h there was no evolution in backscattering, indicating that the suspension was starting to stabilize.
In this way, it could be concluded that before the future administration, the injectable cell suspension should be shacked just before using in order to get a homogeneous hMSCs suspension, avoiding thrombotic or thromboembolic events.
CONCLUSION
In the present study, the stability of a CTMP with hMSCs was studied to be applied in diabetic patients with critical limb ischemia in clinical trial phase I-II, based on the study of the viability of the cells before and after being packaged and stored.
Our results clearly showed that the viability of the hMSCs in a packaging medium comprising albumin 20%, glucose 5% and Ringer's lactate at a concentration of 1  10 6 cells/mL and stored at 4 °C for more than 48 h is maintained above 80%, therefore [41] demonstrated that viability of MSCs in PBS was maintained above 80% but only for 24 h. However, there is no information about which would be the best packaging medium or storage conditions (time and temperature) to maintain the viability for clinical application. For the foreseeable future, cell therapy development will be based on not only in the search for new therapies but also in the study and design of these drugs, in terms of stability and safety, to expand the margins of use over time until administration.
In conclusion, the stability of a medicine is a function of storage conditions and chemical properties of the active ingredients. The conditions used in the stability experiments should reflect situations likely to be encountered during actual sample handling and analysis. Our stability studies in the final medical product were based on showing that characteristics of hMSCs remained unchanged until administration. This is the first study to examine the stability and viability of hMSCs with different excipients for cell suspension packaging at various temperatures, but further studies will be needed to improve the stability of cells for developing a cell medicine. 
